The effect of non-TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritis.

Abstract

Inflammatory arthritides are chronic diseases characterised by an increase in cardiovascular risk, largely attributable to the synergy between high-grade systemic inflammation and an elevated prevalence of traditional cardiovascular risk factors. Amongst the latter, insulin resistance and type 2 diabetes (T2D) play a key position. Previous studies demonstrated a potential insulin-sensitizing effect of anti-TNF biologic medications. For converse, less is known about the role of newer biologics or small molecules. For this reason, we performed a systematic review of the literature in order to identify the available data on the effect on insulin resistance of non-TNF targeting biologics and small molecules approved for the treatment of inflammatory arthritides. The search strategy initially retrieved 486 records of which only 10 articles were selected for inclusion in the final review. According to the available evidence, some of the newest molecules, in particular tocilizumab and abatacept, may have a role in improving insulin sensitivity; for converse, anakinra-mediated effect on glucose metabolism may exploit different facets of T2D pathophysiology, such as the preservation of beta-cell function. However, the data available on this issue are largely inconsistent and future, adequately designed studies are still needed to clarify the differential impact of novel therapeutics on individual pathophysiological features of T2D and other emerging cardiovascular risk factors.

• Authors: Francesco Ursini, Emilio Russo, Piero Ruscitti, Roberto Giacomelli, Giovambattista De Sarro
• Journal: Autoimmunity reviews (Autoimmun Rev) Vol. 17 Issue 4 Pg. 399-404 (Apr 2018) ISSN: 1873-0183 [Electronic] Netherlands
• PMID: 29452240 (Publication Type: Journal Article, Review, Systematic Review)
• Copyright: Copyright © 2018 Elsevier B.V. All rights reserved.

Topics

• Arthritis, Rheumatoid (drug therapy, genetics)
• Diabetes Mellitus, Type 2 (complications)
• Humans
• Insulin Resistance